Janus Henderson Group PLC Sells 24,059 Shares of Immunome, Inc. $IMNM

Janus Henderson Group PLC cut its holdings in Immunome, Inc. (NASDAQ:IMNM) by 2.9% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 808,019 shares of the company’s stock after selling 24,059 shares during the period. Janus Henderson Group PLC’s holdings in Immunome were worth $17,672,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of IMNM. KBC Group NV bought a new stake in shares of Immunome during the 1st quarter worth about $60,000. Strs Ohio acquired a new stake in Immunome in the 4th quarter worth approximately $64,000. Assetmark Inc. lifted its holdings in Immunome by 46.6% in the 1st quarter. Assetmark Inc. now owns 4,535 shares of the company’s stock worth $99,000 after purchasing an additional 1,442 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Immunome during the fourth quarter worth approximately $121,000. Finally, BNP Paribas Financial Markets boosted its position in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares during the period. 44.58% of the stock is owned by institutional investors and hedge funds.

Immunome Price Performance

IMNM opened at $23.01 on Tuesday. Immunome, Inc. has a fifty-two week low of $8.66 and a fifty-two week high of $27.65. The firm’s fifty day moving average price is $21.23 and its two-hundred day moving average price is $22.07. The company has a market capitalization of $2.61 billion, a P/E ratio of -9.67 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, equities research analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on IMNM. Truist Financial raised their target price on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Immunome in a research report on Tuesday, July 21st. HC Wainwright restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Finally, Citigroup reiterated a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Insider Buying and Selling

In other Immunome news, Director Isaac Barchas sold 101,050 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total value of $2,134,176.00. Following the completion of the transaction, the director directly owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kinney Horn sold 1,092 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $25.00, for a total transaction of $27,300.00. Following the completion of the transaction, the insider owned 1,092 shares of the company’s stock, valued at $27,300. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 472,142 shares of company stock valued at $10,262,648 in the last ninety days. 7.21% of the stock is owned by corporate insiders.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.